Mortality associated with influenza and respiratory syncytial virus in the United States.

CONTEXT Influenza and respiratory syncytial virus (RSV) cause substantial morbidity and mortality. Statistical methods used to estimate deaths in the United States attributable to influenza have not accounted for RSV circulation. OBJECTIVE To develop a statistical model using national mortality and viral surveillance data to estimate annual influenza- and RSV-associated deaths in the United States, by age group, virus, and influenza type and subtype. DESIGN, SETTING, AND POPULATION Age-specific Poisson regression models using national viral surveillance data for the 1976-1977 through 1998-1999 seasons were used to estimate influenza-associated deaths. Influenza- and RSV-associated deaths were simultaneously estimated for the 1990-1991 through 1998-1999 seasons. MAIN OUTCOME MEASURES Attributable deaths for 3 categories: underlying pneumonia and influenza, underlying respiratory and circulatory, and all causes. RESULTS Annual estimates of influenza-associated deaths increased significantly between the 1976-1977 and 1998-1999 seasons for all 3 death categories (P<.001 for each category). For the 1990-1991 through 1998-1999 seasons, the greatest mean numbers of deaths were associated with influenza A(H3N2) viruses, followed by RSV, influenza B, and influenza A(H1N1). Influenza viruses and RSV, respectively, were associated with annual means (SD) of 8097 (3084) and 2707 (196) underlying pneumonia and influenza deaths, 36 155 (11 055) and 11 321 (668) underlying respiratory and circulatory deaths, and 51 203 (15 081) and 17 358 (1086) all-cause deaths. For underlying respiratory and circulatory deaths, 90% of influenza- and 78% of RSV-associated deaths occurred among persons aged 65 years or older. Influenza was associated with more deaths than RSV in all age groups except for children younger than 1 year. On average, influenza was associated with 3 times as many deaths as RSV. CONCLUSIONS Mortality associated with both influenza and RSV circulation disproportionately affects elderly persons. Influenza deaths have increased substantially in the last 2 decades, in part because of aging of the population, underscoring the need for better prevention measures, including more effective vaccines and vaccination programs for elderly persons.

[1]  A. Falsey,et al.  Respiratory Syncytial Virus Infection in Adults , 2005, Clinical microbiology reviews.

[2]  W. P. Glezen,et al.  Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. , 1987, The American review of respiratory disease.

[3]  L. Anderson,et al.  Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. , 1990, The Journal of infectious diseases.

[4]  E. Walsh,et al.  Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[5]  H. Sacks,et al.  The Efficacy of Influenza Vaccine in Elderly Persons , 1995, Annals of Internal Medicine.

[6]  K. Nicholson.  Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990 , 1996, Epidemiology and Infection.

[7]  R. Holman,et al.  Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. , 2001, The Journal of infectious diseases.

[8]  R. Davis,et al.  Influenza and the rates of hospitalization for respiratory disease among infants and young children. , 2000, The New England journal of medicine.

[9]  J. Katz,et al.  A nonionic block co-polymer adjuvant (CRL1005) enhances the immunogenicity and protective efficacy of inactivated influenza vaccine in young and aged mice. , 2000, Vaccine.

[10]  L. Simonsen,et al.  Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. , 1998, The Journal of infectious diseases.

[11]  R. Betts,et al.  Protective Efficacy of Combined Live Intranasal and Inactivated Influenza A Virus Vaccines in the Elderly , 1992, Annals of Internal Medicine.

[12]  H M Rosenberg,et al.  Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. , 2001, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[13]  E. Walsh,et al.  Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults , 1999, Journal of medical virology.

[14]  S. Dowell,et al.  Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. , 1996, The Journal of infectious diseases.

[15]  J. Alexander,et al.  Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. , 1999, The Journal of infectious diseases.

[16]  A. Bisno,et al.  Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic , 1971, The American journal of the medical sciences.

[17]  K. Nichol,et al.  Relation between Influenza Vaccination and Outpatient Visits, Hospitalization, and Mortality in Elderly Persons with Chronic Lung Disease , 1999, Annals of Internal Medicine.

[18]  K. Cross,et al.  Respiratory syncytial virus or influenza? , 1993, The Lancet.

[19]  R. Karron,et al.  Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. , 2000, The Journal of infectious diseases.

[20]  K. Nichol,et al.  Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. , 2001, The Journal of infectious diseases.

[21]  L. Simonsen,et al.  The Japanese experience with vaccinating schoolchildren against influenza. , 2001, The New England journal of medicine.

[22]  L. Simonsen,et al.  The impact of influenza epidemics on mortality: introducing a severity index. , 1997, American journal of public health.

[23]  D. Fleming,et al.  Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study , 2001, The Lancet.

[24]  E. Walsh,et al.  Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. , 1996, Vaccine.

[25]  Keiji Fukuda,et al.  Medical Care Capacity for Influenza Outbreaks, Los Angeles , 2002, Emerging infectious diseases.

[26]  K. Nichol,et al.  Effectiveness of influenza vaccine in the elderly. , 1996, Gerontology.

[27]  R. Holman,et al.  Bronchiolitis-associated hospitalizations among US children, 1980-1996. , 1999, JAMA.

[28]  A. Falsey,et al.  Acute Respiratory Tract Infection in Daycare Centers for Older Persons , 1995, Journal of the American Geriatrics Society.

[29]  B. Murphy,et al.  Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees , 2000, Journal of Virology.

[30]  C. Cox,et al.  A study of the impact of influenza on the functional status of frail older people. , 1998, Archives of internal medicine.

[31]  J. Hedlund,et al.  Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study , 2001, The Lancet.

[32]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[33]  R. Douglas.  Influenza: the disease and its complications. , 1976, Hospital practice.

[34]  K. Nichol,et al.  Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. , 1998, Archives of internal medicine.

[35]  Margo J. Anderson,et al.  The Census , 1921, The Hospital.

[36]  K. Edwards,et al.  Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. , 2002, Archives of internal medicine.

[37]  M E Halloran,et al.  Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.

[38]  Keiji Fukuda,et al.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[39]  N. Cox,et al.  Surveillance for influenza--United States, 1994-95, 1995-96, and 1996-97 seasons. , 2000, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.